Vulvovaginitis therapy in pregnant women as a preventative method of the perinatal complications development

Authors

DOI:

https://doi.org/10.18370/2309-4117.2019.48.56-58

Keywords:

pregnancy, vulvovaginitis, perinatal complications, dequalinium chloride, Femiclin

Abstract

Disorders of the vaginal biocenosis in pregnant women takes the leading place in the etiology of the main obstetric and perinatal complications. Careful attention to the biocenosis of pregnant woman is also due to the fact that the formation of fetus bacterial communities occurs long before its birth.

Purpose of the study. Evaluation of the effectiveness of chlorine-containing antiseptics for vulvovaginal infections during pregnancy as a method for the prevention of perinatal complications.

Materials and methods. 62 pregnant women in the second and third trimester of gestation were examined. All patients underwent clinical examination, bacterioscopic and bacteriological study of vaginal secretions. Pregnant women with verified vulvovaginal infection received the dequalinium chloride (Femiclin drug), which was used 1 vaginal tablet daily for 6 days. The efficacy of treatment was evaluated according to clinical data before treatment, on the 3rd and 7th day of observation and according to laboratory tests before and after treatment.

Study results and discussion. Bacterioscopic and bacteriological examination of vaginal contents showed dysbiotic disorders of the vaginal flora in 77.4% (48) of pregnant women, in 22.9% (11) patients were diagnosed bacterial vaginosis, in 33.3% (16) candidal colpitis, in 31.3% (15) aerobic vaginitis, in 12.5% (6) trichomonas colpitis. Normocenosis in pregnant women was observed in 22.6% of cases. After therapy with Femiclin clinical symptoms was absent in 45 pregnant women (93.8%). A laboratory test after treatment confirmed the effectiveness of the proposed therapy in the same number of patients (93.8%). Conclusions. Femiclin showed high sensitivity against the main causative agents of vulvovaginal infection: optional anaerobes (94.1%), fungi (93.8%) and microaerophilic microorganisms (93.3%). The high efficacy of the drug in case of a vulvovaginal infection during pregnancy allows to recommend it for widespread use to prevent perinatal complications.

Author Biography

О. В. Кравченко, Bukovinian State Medical University, Chernivtsi

MD, professor, Head of the Obstetrics, Gynecology and Perinatology Department

References

  1. Limanska, A.Y., Voloshina, T.V., Baider, A.K., Davydova, Y.V. “Restoring the balance of vaginal and intestinal biotope in the preconception period after antibiotic therapy.” Perinatology and Pediatrics 1.69 (2017): 33–8.
  2. Zhuk, S.I., Shliakhtina, A.A. “Management Biotopes of Women. New Approaches.” Woman Health 6.132 (2018): 34–6.
  3. Kosei, N.V., Tatarchuk, T.F., Vetokh, G.V. “Empirical therapy of vaginitis as a method of preventing the development of an ascending infection.” Reproductive endocrinology 2(4) (2012): 70–4.
  4. Seytkhanova, B.T., Shapambayev, N.Z., Olgaeva, R.R., Kalmenova, P.E. “Microbiocenosis of the vagina and pregnant women.” Science and health care 1 (2014): 70–1.
  5. Rakhmatulina, M.R. “Modern approaches to the therapy of vulvovaginitis caused by opportunistic microorganisms, taking into account the antibacterial resistance of infectious agents.” Bulletin of Dermatology and Venereology 2 (2013): 44–52.
  6. Cucchiara, S. “Baby microbiome management.” I International Summit dedicated to the problems of microbiota. Paris. March 10, 2017.
  7. Kovachev, S. “Deference factors of vaginal lactobacilli.” Critical Reviews in Microbiology 44.1 (2018): 31–9.
  8. Prince, A.L., et al. “The microbiome, parturition, and timing of birth: more questions than answers.” J Reprod Immunol 104–105 (2014): 12–9.
  9. Freitas, A.C., Chaban, B., Bockinf, A. “The vaginal microbiome of pregnant women is less rich and diverse, with lower prevalence of Mollicutes, compared to non-pregnant women.” Scientific Reports 7 (2017): 9212.
  10. Wang, Z., Fu, L., Xiong, Z., et. al. “Diagnosis and microecological characteristics of aerobic vaginitis in outpatients based on preformed enzymes.” Taiwanese Journal of Obstetrics and Gynecology 55.1 (2016): 40–4. DOI: 10.1016/j.tjog.2015.06.012

Downloads

Published

2019-10-03

How to Cite

Кравченко, О. В. (2019). Vulvovaginitis therapy in pregnant women as a preventative method of the perinatal complications development. REPRODUCTIVE ENDOCRINOLOGY, (48), 56–58. https://doi.org/10.18370/2309-4117.2019.48.56-58

Issue

No. 48 (2019)

Section

Pregnancy and childbirth

License

Copyright (c) 2019 О. В. Кравченко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.